AG Bumm

Thomas Bumm: Next Generation Antibody Therapy

Summary

Therapeutic antibodies against cancer dominate one of the fastest growing fields of modern drug discovery. All current antibodies address a single target antigen. Because of tumour-specific antigens do not exist, these targets frequently represent differentiation antigens, shared by normal and malignant cells and whose engagement often entails serious side effects.
Our research team is working with a novel antibody based bimolecular pro-drug approach, redirecting CD3 positive T lymphocytes for cancer cell destruction by addressing the combination of two antigens. We plan to further develop next generation antibody therapy in close collaboration with other CCC-Mainfranken research groups for various malignant entities

Recent Publications

Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC, Chatterjee M. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. 2013. Br J Haematol. 160(4):465-76.

Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. 2011. Blood. 118(24):6392-8.

Bumm T, Deininger J, Newell AH, Lawce H, Olson S, Mauro M, Druker B, Deininger M. Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. 2010. Leukemia. 24(8):1525-8.

Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW.BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. 2010. Blood. 116(17):3278-85.

Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. 2010. Blood. 115(25):5232-40.